Menu Menu


GLAXF Financials       Clear


GLAXF        0001131399    
Filing Date Form Type Description Document
2023-10-12 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-10-11 6-K ZANTAC (RANITIDINE) LITIGATION View Document
2023-10-10 SC 13D/A AMENDMENT TO FORM SC 13D View Document
2023-10-10 6-K GSK AND ZHIFEI ANNOUNCE VACCINE PARTNERSHIP View Document
2023-10-06 6-K CURRENT REPORT View Document
2023-10-06 6-K GSK COMPLETES SALE OF SHARES IN HALEON PLC View Document
2023-10-02 25-NSE View Document
2023-10-02 6-K TOTAL VOTING RIGHTS View Document
2023-09-27 6-K DIRECTORATE CHANGE View Document
2023-09-25 6-K GSK RSV VACCINE FOR OLDER ADULTS APPROVED IN JAPAN View Document
2023-09-21 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-09-19 6-K APRETUDE FOR PREP RECEIVES EMA APPROVAL View Document
2023-09-18 6-K FDA APPROVES OJJAARA (MOMELOTINIB) View Document
2023-09-13 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-09-11 SC 13D/A AMENDMENT TO FORM SC 13D View Document
2023-09-11 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-09-11 6-K MOMELOTINIB FILING ACCEPTED IN JAPAN View Document
2023-09-06 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-09-01 6-K TOTAL VOTING RIGHTS View Document
2023-09-01 6-K GSK'S NUCALA CRSWNP SUBMISSION ACCEPTED IN JAPAN View Document
2023-08-31 6-K HOLDING(S) IN COMPANY View Document
2023-08-31 6-K HOLDING(S) IN COMPANY View Document
2023-08-25 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-08-23 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-08-23 6-K SHINGRIX DATA DEMONSTRATE 100% EFFICACY IN CHINA View Document
2023-08-22 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-08-10 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-08-09 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-08-01 6-K TOTAL VOTING RIGHTS View Document
2023-07-31 6-K FDA APPROVES NEW USE FOR JEMPERLI PLUS CHEMO View Document
2023-07-31 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-07-28 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-07-26 6-K 2ND QUARTER RESULTS View Document
2023-07-24 6-K CABOTEGRAVIR LA FOR PREP RECEIVES POSITIVE CHMP View Document
2023-07-20 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-07-20 SC 13D/A AMENDMENT TO FORM SC 13D View Document
2023-07-17 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-07-13 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-07-03 6-K TOTAL VOTING RIGHTS View Document
2023-06-28 6-K GSK COMPLETES ACQUISITION OF BELLUS HEALTH View Document
2023-06-27 6-K FDA FAST TRACK FOR GONORRHOEA VACCINE CANDIDATE View Document
2023-06-26 6-K GSK DAPRODUSTAT GAINS POSITIVE EMA CHMP OPINION View Document
2023-06-26 6-K SHINGRIX APPROVED IN JAPAN FOR ADULTS 18 AND OVER View Document
2023-06-23 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-06-23 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-06-23 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-06-23 6-K STATEMENT: ZANTAC (RANITIDINE) LITIGATION View Document
2023-06-22 6-K GSKS AREXVY RECOMMENDED BY ACIP View Document
2023-06-21 11-K ANNUAL REPORT View Document
2023-06-21 11-K ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE View Document
2023-06-21 6-K SEASON TWO DATA FOR GSK AREXVY RSV OA VACCINE View Document
2023-06-16 6-K EXTENSION OF FDA REVIEW PERIOD FOR MOMELOTINIB View Document
2023-06-12 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-06-07 6-K EU AUTHORISATION OF GSKS RSV VACCINE AREXVY View Document
2023-06-06 6-K GSK RECEIVES US FDA FILE ACCEPTANCE FOR JEMPERLI View Document
2023-06-01 6-K TOTAL VOTING RIGHTS View Document
2023-05-30 SD SPECIALIZED DISCLOSURE View Document
2023-05-22 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-05-16 SC 13D/A AMENDMENT TO FORM SC 13D View Document
2023-05-15 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-05-15 6-K BLOCK LISTING INTERIM REVIEW View Document
2023-05-12 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-05-12 6-K MENABCWY VACCINE PRELIMINARY PHASE III RESULTS View Document
2023-05-12 6-K STATEMENT: ZANTAC LITIGATION UPDATE BC CANADA View Document
2023-05-12 6-K GSK COMPLETES SALE OF SHARES IN HALEON PLC View Document
2023-05-12 6-K CURRENT REPORT OF FOREIGN ISSUER View Document
2023-05-09 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-05-04 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-05-03 6-K RESULT OF AGM View Document
2023-05-03 6-K US FDA APPROVES GSKS RSV VACCINE FOR OLDER ADULTS View Document
2023-05-02 6-K TOTAL VOTING RIGHTS View Document
2023-04-28 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-04-27 6-K GSK RSV OA VACCINE GAINS POSITIVE EMA CHMP OPINION View Document
2023-04-26 6-K 1ST QUARTER RESULTS View Document
2023-04-25 6-K EMA VALIDATES JEMPERLI FILING FOR NEW INDICATION View Document
2023-04-20 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-04-19 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-04-18 6-K GSK REACHES AGREEMENT TO ACQUIRE BELLUS HEALTH INC View Document
2023-04-17 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-04-17 6-K GEPOTIDACIN POSITIVE PHASE III DATA View Document
2023-04-17 20-F/A 20-F/A View Document
2023-04-03 6-K TOTAL VOTING RIGHTS View Document
2023-03-28 6-K POSITIVE PHASE III RUBY RESULTS FOR JEMPERLI View Document
2023-03-27 6-K PUBLICATION OF 2023 AGM NOTICE View Document
2023-03-24 6-K STATEMENT: ZANTAC (RANITIDINE) LITIGATION View Document
2023-03-21 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-03-20 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-03-15 EFFECT View Document
2023-03-14 6-K POSITIVE PHASE III RESULTS FOR MENABCWY VACCINE View Document
2023-03-14 6-K NUCALA NDA ACCEPTED FOR REVIEW IN CHINA View Document
2023-03-13 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-03-10 POS AM POS AM View Document
2023-03-10 6-K GSK ANNUAL REPORT 2022 ON FORM 20-F View Document
2023-03-10 IRANNOTICE IRANNOTICE View Document
2023-03-10 20-F 20-F View Document
2023-03-10 6-K GSK PUBLISHES ANNUAL REPORT 2022 View Document
2023-03-02 6-K FDA AD COM VOTES TO SUPPORT GSK RSV OA VACCINE View Document
2023-03-01 6-K TOTAL VOTING RIGHTS View Document
2023-02-27 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-02-23 6-K DIRECTOR/PDMR SHAREHOLDING View Document

Find registration statements, periodic reports, and other forms by typing ticker symbol of a company.

Ticker:

(402) 804-8299